
Free Daily Podcast Summary
by Max Brennan - Biotech HeadHunter
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Get ready for an immersive experience into the world of biotech with The BioHub.
The most recent episodes — sign up to get AI-powered summaries of each one.
In this episode of The BioHub by Avetix, I’m joined by Carmine Stengone, President & CEO of Contineum Therapeutics.Carmine began his career as an organic chemist before realising that his biggest impact might come outside the lab. That decision led him into business development, venture, company building and eventually the CEO seat.We discuss why he joined Contineum, the thinking behind PIPE-791, the company’s work in pulmonary fibrosis, taking Contineum public in 2024, and the challenge of balancing public-market expectations with the much longer timelines of drug development.Carmine also shares the mentors who shaped his career, the lessons he’s learned building biotech companies, and what comes next for Contineum.
In this episode of the BioHub podcast, Amber Hayes is joined by Hannah Shen, Founder and CEO of Kekulai, an end-to-end agentic drug discovery company focused on developing first-in-class medicines.Drawing on her experience at Benchling and BridgeBio, Hannah shares her journey into biotech and the vision behind Kekulai's agentic discovery platform, Alchemy.Together, they explore the challenges of building reliable AI agents for high-stakes scientific decisions, balancing human expertise with autonomous workflows, and why more data doesn't always mean better drug discovery.Hannah also discusses how Kekulai is running three drug A fascinating conversation about the future of agentic AI, scientific reasoning and what it takes to turn emerging technology into real medicines.
We were delighted to be joined by Susan Hill, CEO and founder of Mestag Therapeutics, a biotechnology company pioneering new approaches to treating cancer and inflammatory diseases through the emerging field of fibroblast immunology.Susan brings more than 25 years of experience across the biotechnology, pharmaceutical and investment industries. She has held senior leadership positions at Merck KGaA, Alexion, Freeline Therapeutics and Gyroscope Therapeutics, where she served as Chief Business Officer before its acquisition by Novartis.She founded Mestag Therapeutics in 2020, building the company around some fascinating science and leading it through significant financing, strategic pharmaceutical partnerships and its evolution into a clinical-stage biotech.Mestag is tackling an area of biology that has historically been overlooked, exploring how fibroblasts interact with the immune system and how those interactions could unlock entirely new therapeutic approaches for patients.Today, we'll be discussing Susan's journey through the field, the experience of building and scaling biotech companies, the science behind Mestag, and what it takes to translate emerging biology into impactful medicines.
Today on The BioHub, I'm delighted to be joined by Dr. Aarash Bordbar, Co-Founder and Chief Executive Officer of Sinopia Biosciences.Aarash has built his career at the intersection of computational biology, systems biology and drug discovery, with a particular focus on understanding complex biological systems and translating that knowledge into new therapeutic approaches.He co-founded Sinopia Biosciences with a vision of harnessing computational modelling and data-driven approaches to transform drug discovery, bringing together biology, mathematics and technology to tackle some of the most challenging questions in medicine.Today, we're going to explore Aarash's journey through the field, the founding and evolution of Sinopia, how computational biology is changing the drug discovery landscape, and what the future might look like as AI and advanced modelling become increasingly integrated into biotechnology.
In this episode of The BioHub, Amber is joined by Dr. Sean Ekins, Founder and CEO of Collaborations Pharmaceuticals.Sean shares his perspective on the evolving role of machine learning in drug discovery, how computational approaches can support rare and neglected disease research, and what it really takes to move from prediction to meaningful therapeutic development.They also discuss the opportunities and limitations of AI in chemistry, the importance of scientific collaboration, and some of the wider questions around responsible innovation and dual-use risk as generative drug discovery continues to develop.
n this episode of The BioHub, we welcome Jason Goodson, Chief Operating Officer at PleoPharma, a clinical-stage biotechnology company developing innovative treatments for cannabis use disorder and cannabis withdrawal syndrome.With millions of Americans affected by cannabis use disorder and no FDA-approved medications specifically targeting cannabis withdrawal, PleoPharma is working to address a significant unmet need through its lead candidate, PP-01, now in pivotal Phase 3 development.Jason shares insights into the growing market for addiction therapeutics, the clinical and commercial potential of PP-01, and the challenges of bringing a first-in-class treatment to market.We also explore the strategic decisions behind scaling a clinical-stage biotech, from financing and partnerships to commercial readiness, leadership, and building the right team for future growth.
Today, we’re joined by Erick Lucera, Chief Financial Officer, and Vikram Ranade, Chief Business Officer at Dyne Therapeutics. We’ll be discussing their individual journeys through biotech, what attracted them to Dyne, and the company’s mission to develop transformative treatments for people living with genetically driven neuromuscular diseases. We’ll also explore the strategy behind building a biotech towards commercialisation, the financial and business development challenges involved, and their perspectives on the wider biotech landscape.
In this episode of The BioHub Podcast, Ben is joined by Dr. John Yu, CEO and Chairman of Kairos Pharma, a clinical-stage biotechnology company developing innovative therapies to overcome drug resistance and immune suppression in cancer.Dr. Yu brings a unique perspective from his extensive career in neurosurgery, oncology, immunology, and biotechnology entrepreneurship. Together, they explore his journey from academic medicine into biotech leadership, the science behind Kairos Pharma's approach to tackling cancer drug resistance, and the development of its lead candidate, ENV105, which targets CD105 to potentially restore sensitivity to existing cancer treatments.The conversation also examines the challenges of translating academic discoveries into clinical therapies, building and financing an emerging biotechnology company, and the opportunities ahead for improving cancer treatment outcomes.An insightful discussion on scientific innovation, entrepreneurship, and the journey from breakthrough research to meaningful patient impact.
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
Listeners also like.

Biotech Hangout
A weekly discussion covering biotech news, data, deals, and regulatory updates featuring industry leaders and experts.

The Long Run with Luke Timmerman
In-depth conversations with biotech leaders navigating the challenges and opportunities of advancing science for human health.

Huberman Lab
Explores neuroscience and science-based tools for understanding and improving brain function, behavior, and health.

Renee Belz & Lauren Sambataro
Biohacker Babes

The Hunter Williams Podcast
Explores cutting-edge science in peptides, hormone optimization, and biohacking with experts pushing the limits of human performance.

The a16z Show
Explores technology and cultural shifts shaping the future through conversations with industry leaders and innovators.

The AI XR Podcast
Insightful interviews with tech founders and executives on AI, virtual reality, augmented reality, and the future of spatial computing.

Summation with Auren Hoffman
Explores transformative ideas with leaders in tech, business, and government through in-depth conversations.

The VPZD Show
Two physicians discuss healthcare, medicine, and policy from a contrarian, middle-ground perspective.

Biosphere 2 Podcast
Aaron Bugaj

No Priors: Artificial Intelligence | Technology | Startups
Discusses AI advancements and implications with researchers, engineers, and founders shaping the future of artificial intelligence.

The Room Podcast
Tech founders and funders share behind-the-scenes stories from pivotal moments in their careers.
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Get ready for an immersive experience into the world of biotech with The BioHub.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from The BioHub - by Avetix in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of The BioHub - by Avetix as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Max Brennan - Biotech HeadHunter.
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
The BioHub - by Avetix publishes daily. Our AI generates a summary within hours of each new episode.
The BioHub - by Avetix covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.